A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years
To evaluate the safety and tolerability of 15-valent HPV vaccine in 9-45year-old participants.
HPV Infection|HPV-Related Carcinoma|Genital Wart|HPV-Related Intraepithelial Neoplasia
BIOLOGICAL: Placebo|BIOLOGICAL: 15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha)
Percentage of Participants With Adverse Events, AE of local and systemic reactions within 30 minutes after each dose, Up to 30 minutes after any vaccination|Percentage of Participants With Solicited Adverse Events, The percentage of participants with one or more solicited AEs was assessed., Up to 14 days after any vaccination|Percentage of Participants With Unsolicited Adverse Events, The percentage of participants with one or more unsolicited AEs was assessed., Up to 30 days after any vaccination|Percentage of Participants With Serious Adverse Events, The percentage of participants with one or more SAEs was assessed, From Day 0 after the first dose of vaccination to 6 months after the thrid dose|Percentage of Female Participants With Pregnancy Events, The percentage of participants with Pregnancy Events was assessed, From Day 0 after the first dose of vaccination to 6 months after the thrid dose
A phase 1 random, double blind, placebo control trail was plan to conducted in 72 healthy participants in the 2 age groups(18-45 years old and 9-17 years old). The 72 subjects to be inoculated with middle and high dose vaccine first in sequence if there was no safety issue.